

RESEARCH ARTICLE

Risk prediction for *Staphylococcus aureus* surgical site infection following cardiothoracic surgery; A secondary analysis of the V710-P003 trial

Fleur P. Paling^{1*}, Karina Olsen¹, Kristin Ohneberg², Martin Wolkewitz², Vance G. Fowler Jr.³, Mark J. DiNubile⁴, Hasan S. Jafri⁵, Frangiscos Sifakis⁶, Marc J. M. Bonten^{1,7}, Stephan J. Harbarth⁸, Jan A. J. W. Kluytmans^{1,9}

1 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands, **2** Institute for Medical Biometry and Statistics, University Medical Center Freiburg, Freiburg, Germany, **3** Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, United States of America, **4** Merck & Company Incorporation, Kenilworth, New Jersey, United States of America, **5** MedImmune, Gaithersburg, Maryland, United States of America, **6** AstraZeneca Pharmaceuticals LP, Gaithersburg, Maryland, United States of America, **7** Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands, **8** Geneva University Hospitals and Medical School, Geneva, Switzerland, **9** Amphia Hospital, Breda, The Netherlands

* f.p.paling@umcutrecht.nl



OPEN ACCESS

Citation: Paling FP, Olsen K, Ohneberg K, Wolkewitz M, Fowler VG Jr., DiNubile MJ, et al. (2018) Risk prediction for *Staphylococcus aureus* surgical site infection following cardiothoracic surgery; A secondary analysis of the V710-P003 trial. PLoS ONE 13(3): e0193445. <https://doi.org/10.1371/journal.pone.0193445>

Editor: Yhu-Chering Huang, Chang Gung Memorial Hospital, TAIWAN

Received: February 16, 2017

Accepted: January 9, 2018

Published: March 21, 2018

Copyright: © 2018 Paling et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: The data used for this study (POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS) were obtained from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and are available to other researchers upon request from Merck. Merck's data-sharing policy, including requests and restrictions, is accessible at http://engagezone.merck.com/ds_documentation.php. Requests for access to the study data can be

Abstract

Background

Identifying patients undergoing cardiothoracic surgery at high risk of *Staphylococcus aureus* surgical site infection (SSI) is a prerequisite for implementing effective preventive interventions. The objective of this study was to develop a risk prediction model for *S. aureus* SSI or bacteremia after cardiothoracic surgery based on pre-operative variables.

Materials/Methods

Data from the Merck Phase IIb/III *S. aureus* vaccine (V710-P003) clinical trial were analyzed. In this randomized placebo-controlled trial, the effect of preoperative vaccination against *S. aureus* was investigated in patients undergoing cardiothoracic surgery. The primary outcome was deep/superficial *S. aureus* SSI or *S. aureus* bacteremia through day 90 after surgery. Performance, calibration, and discrimination of the final model were assessed.

Results

Overall 164 out of 7,647 included patients (2.1%) developed *S. aureus* infection (149 SSI, 15 bacteremia, 28 both). Independent risk factors for developing the primary outcome were pre-operative colonization with *S. aureus* (OR 3.08, 95% confidence interval [CI] 2.23–4.22), diabetes mellitus (OR 1.87, 95% CI 1.34–2.60), BMI (OR 1.02 per kg/m², 95% CI 0.99–1.05), and CABG (OR 2.67, 95% CI 1.91–3.78). Although vaccination had a significant (albeit modest) protective effect, it was omitted from the model because its addition did not significantly change the coefficients of the final model and V710-vaccine development has

submitted through the EngageZone site or via e-mail (dataaccess@merck.com). The authors confirm that others can access these data in the same manner as the authors did, as described above, and that the authors did not have special data access privileges that other researchers would not have.

Funding: Commercial organizations participating in this project are Merck & Co., Inc., Kenilworth, NJ, USA; AstraZeneca, LP; MedImmune. This research project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115523 resources which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution. The commercial organizations AstraZeneca and MedImmune partly funded the subsidies that came from IMI. This project used data collected earlier in a randomized-controlled study sponsored and funded by Merck & Co. Inc., Kenilworth, NJ, USA. Merck & Co., provided salary support for MDN and grant support for VF, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. The funder (IMI) provided support in the form of salaries for authors KrO, MW, SH, MB, FP, JK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. The funder (AstraZeneca) provided support in the form of salaries for authors FS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. The funder (MedImmune) provided support in the form of salaries for authors HJ, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.

Competing interests: MDN is an employee of Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and owns stock and stock options in the company. Inc. FS is an employee of AstraZeneca, LP. HJ is an employee of MedImmune. This project is funded by the Innovative Medicine Initiative Undertaking (IMI). The commercial organizations AstraZeneca and MedImmune partly funded the subsidies that came

been discontinued due to insufficient efficacy. The final prediction model had moderate discriminative accuracy (AUC-value, 0.72).

Conclusion

Pre-operative *S. aureus* colonization status, diabetes mellitus, BMI, and type of surgical procedure moderately predicted the risk of *S. aureus* SSI and/or bacteremia among patients undergoing cardiothoracic surgery.

Introduction

Surgical site infection (SSI) with or without bacteremia is a common post-operative complication responsible for increased morbidity, mortality, and health care costs[1–3]. The most important cause of SSIs among patients undergoing clean surgery is *Staphylococcus aureus* [4–6] which frequently colonizes the nares and skin in the healthy population. In preoperative patients, carriage is associated with an elevated risk for post-operative SSI and bacteremia [7,8]. Yet the ability to identify preoperative patients at highest risk for *S. aureus* SSI or post-operative bacteremia is inadequate [9]. As preemptive pathogen-specific preventive interventions are under development, it is important to reliably identify those patients at substantial risk for this complication [10].

For this study, data from the Merck Phase IIb/III *S. aureus* vaccine study (V710-P003) were analyzed [11]. This double-blinded, randomized, placebo-controlled trial investigated the effect of a pre-operative vaccine targeting *S. aureus* on the incidence of postoperative *S. aureus* bacteremia and/or deep sternal wound infection in adult patients undergoing cardiothoracic surgery through postoperative day 90. V710 was not sufficiently efficacious in preventing the primary endpoint by prespecified criteria, and overall mortality rates for the placebo or vaccine group were not significantly different. The trial was stopped prematurely after interim analysis showed lack of efficacy as well as a numerically higher mortality rate in the subset of vaccine recipients developing *S. aureus* infections. Pre-operative *S. aureus* colonization status was documented as part of protocol-stipulated procedures.

In the current *post hoc* analysis of the prospectively collected data from this clinical trial, we aimed to develop a pathogen-specific risk prediction model for *S. aureus* SSI and/or bacteremia in patients after cardiothoracic surgery based on information ascertainable preoperatively.

Materials and methods

Data from the randomized, double-blind, placebo-controlled trial of Merck Phase IIb/III *S. aureus* vaccine (V710-P003, registered at clinicaltrials.gov under the identifier NCT00518687) were used for this *post hoc* analysis [11]. Because the clinical trial was stopped in part due to unacceptably low vaccine efficacy, we included both placebo and vaccine recipients in this analysis. Data were available on all efficacy outcomes. Decolonization procedures and pre-operative surgical prophylaxis were provided according to local standards of care for the international sites participating in the trial. However, decolonization methods were neither mandated by protocol nor routinely recorded. The original study protocol was approved by the institutional review boards or ethical review committees at each site and executed in accordance with Good Clinical Practice guidelines.

from IMI. This project used data collected earlier in a randomized-controlled study sponsored and funded by Merck & Co. Inc., Kenilworth, NJ, USA. Author VF received grant support from Merck & Co. The data used for this project were obtained from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. The data are covered EP Patent No. EP 1 651 166 B8 entitled POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS. There are no further patents, products in development or marketed products to declare. Data are available upon reasonable request. Merck's data-sharing policy, including requests and restrictions, is accessible at http://engagezone.merck.com/ds_documentation.php. Requests for access to the study data can be submitted through the EngageZone site or via e-mail (odataaccess@merck.com).

Patient population

Adult patients undergoing elective cardiothoracic surgery were eligible for inclusion. Exclusion criteria, described in more detail elsewhere, included active infection, pregnancy, and immunosuppression[11,12].

Primary outcome

The primary outcome was a binary (yes/no) composite endpoint through day 90 after surgery, which included at least one of the following *S. aureus* diagnoses: deep/superficial sternal wound infection (including mediastinitis), deep/superficial harvest site infection, and bacteremia (defined as at least one positive blood culture growing *S. aureus*). All cases were adjudicated by an independent committee using diagnostic criteria established by the Center for Disease Control and Prevention (CDC) [13].

Potential predictors and their management

A list of candidate predictors was defined prior to initiating this analysis, based on clinical judgment and availability in the database, including pre-operative *S. aureus* colonization status, pre-operative antibiotic use, diabetes mellitus, type of cardiothoracic procedure, body mass index (BMI), age, and sex.

We defined a patient to be colonized if nasal *S. aureus* carriage was documented by culture at any moment before surgery. This assumption was chosen because literature indicates that colonization status is largely dependent on the patient's constitution and thus relatively constant over time[7].

Pre-operative antibiotic use was defined as any systemic antibiotic use within 6 months before surgery, excluding pre-operative prophylaxis. A timeframe of 6 months pre-operatively was chosen, considering that previous studies had shown that the microbiome can be affected after antibiotic usage for this period of time[14]. Diabetes mellitus was coded as yes if there was a confirmed diagnosis of diabetes mellitus, regardless of duration of disease or need for diabetic agents. Gestational diabetes was not included. Surgical procedure type was dichotomized to coronary artery bypass grafting (CABG) or not. The combination of CABG and cardiac valve surgery was coded as CABG. Cardiac valve surgery alone or other cardiothoracic surgery types including median sternotomy were coded as 'no CABG'.

Age and BMI were used as continuous variables; it was checked whether fractional polynomials improved model performance[15]. Missing values ($n = 152$) of *S. aureus* colonization status were imputed using multiple imputation techniques[16].

Univariate logistic regression analysis was performed on the mentioned variables. Variables with a univariate $p \leq 0.157$ were entered into the final multivariable model, roughly corresponding to the selection threshold based on the Akaike information criterion when considering p -values [17]. Tests of interactions between pre-operative *S. aureus* colonization status and BMI or diabetes mellitus were performed (p -value < 0.05).

Regression model and model performance

A logistic regression model was fitted with the variables described above. Overall model performance was assessed by measuring the explained variation (Nagelkerke R^2)[18]. Calibration of the model was assessed by plotting the observed proportion of events against the predicted risks for groups defined by ranges of individual predicted risks. For the assessment of the discrimination of the model, a receiver operating characteristic (ROC) curve was plotted and the

area under the curve (AUC or c-statistic) was computed. Internal validation was assessed by performing 200 bootstrap samples.

Sensitivity analyses

Competing events. Patients might have died within 90 days post-surgery without reaching the primary outcome, which means that death is a competing event for the primary outcome. As a sensitivity analysis, a Fine & Gray model was fitted to account for the time-to-event, considering death as a competing event [19]. Subdistribution hazard ratios for SSI were calculated as an alternative measure (by acknowledging the time-dependency) for the odds ratios. Cumulative incidence functions were calculated with stratification by risk score groups using the Aalen-Johansen estimator[20].

Vaccine effect. Considering that we used a slightly different primary outcome compared to the initial study (originally superficial or harvest site infections were not included), it was assessed whether a vaccine-effect was present (p-value <0.05) and whether adding vaccination to the model significantly altered the effect estimates.

All statistical analyses were performed using R version 2.10.00. [21]

Results

In the final analysis, 7,647 patients were included. Their baseline characteristics are described in Table 1. Overall 165 out of 7,647 included patients (2.1%) developed *S. aureus* SSI and/or bloodstream infection, including 122 (1.6%) patients with SSI without bacteremia, 28 (0.4%) patients with bacteremic SSI, and 15 patients (0.2%) with post-operative bacteremia without SSI.

Predictors of *S. aureus* SSI and/or bacteremia

Several pre-operative variables were univariately associated with the primary outcome: pre-operative colonization status with *S. aureus* (OR 3.07, 95% confidence interval [CI] 2.23–4.20), diabetes mellitus (OR 2.45, 95% CI 1.78–3.34), CABG (OR 3.01, 95% CI 2.24–4.35), and BMI (OR 1.04 per kg/m² increase, 95% CI 1.02–1.07). No significant interaction was found between pre-operative *S. aureus* colonization and either BMI or diabetes mellitus (p-values 0.196 and 0.089, respectively).

Table 1. Baseline characteristics.

| | With outcome N = 165 | Without outcome N = 7,482 | Total N = 7,647 |
|---|-------------------------|------------------------------|--------------------|
| Age (years) | 64.9 (10.8) | 63.9 (12.4) | 63.9 (12.4) |
| Gender: female | 53 (30.0) | 2,467 (33.0) | 2,520 (33.0) |
| Pre-operative <i>S. aureus</i> colonization | 67 (42.0) | 1,364 (18.2) | 1,431 (18.7) |
| BMI (kg/M ²) | 29.0 (5.7) | 27.6 (5.3) | 27.6 (5.3) |
| Diabetes mellitus | 71 (45.3) | 1,765 (23.6) | 1836 (24.0) |
| Pre-operative antibiotic use | 10 (5.3) | 653 (8.7) | 663 (8.7) |
| CABG | 113 (68.5) | 3,075 (41.1) | 3,188 (41.7) |
| Vaccination | 66 (40.1) | 3,747 (50.0) | 3,813 (49.9) |
| Death* | 7 (4.2) | 229 (3.1) | 236 (3.1) |

Values are given as means (SD), and numbers (%). SD = standard deviation, BMI = body mass index, CABG = coronary artery bypass grafting

*Death within 90 days post-surgery

<https://doi.org/10.1371/journal.pone.0193445.t001>

Independent risk factors identified during multivariate analysis were pre-operative colonization status (OR 3.08, 95% CI 2.23–4.22), diabetes mellitus (OR 1.87, 95% CI 1.34–2.60), CABG (OR 2.67, 95% CI 1.91–3.78) and BMI (OR 1.02 per unit increase, 95% CI 0.99–1.05) (Table 2).

Model performance

The mean explained variation of the model as indicated by the Nagelkerke R^2 was 0.08. The distribution of predicted risks for the event of interest was highly skewed to the left, with more patients in the low risk categories than in the high-risk categories. Only 8.2% of the patients had a risk of $\geq 5\%$. Of the 209 *S. aureus* colonized, diabetic patients undergoing CABG (i.e. who had all three major risk factors), the risk of developing the event was 11% (n = 23). Of the 3012 patients without any preoperative risk factor, 28 (0.9%) developed the event.

Fig 1 shows a calibration plot with average agreement between the observed events and the predicted risks by ranges of individual predicted risks (Hosmer-Lemeshow $\chi^2 = 13.0$, p = 0.11). Discrimination of the model was average, with an area under the ROC curve of 0.72 (95% CI 0.68–0.76) (Figs 2 and 3).

Internal validation

The stability of the final model was further assessed in 200 bootstrap samples. Using these samples, we derived an R^2 of 0.07 and AUC of 0.72 after correction for optimism. The Somers' Dxy rank correlation between predicted probabilities and observed responses was 0.43 (0 indicating completely random predictions and 1 indicating perfect predictions).

Sensitivity analysis

Competing risks. A total number of 236 patients died within 90 days post-surgery. Of these, 229 had not yet developed the primary event of interest. Using the Fine & Gray competing risks analysis to assess whether the subdistribution hazard ratios differ from the odds ratios from the logistic regression model, the estimates did not change significantly (maximum observed change was 2%). Hence, the effect of death as a competing risk can largely be ignored.

Vaccine effect. Vaccination was univariately associated with the primary outcome. V710 was protective against *S. aureus* infection (OR 0.67, 95% CI 0.48–0.91, p = 0.011), and

Table 2. Univariate and multivariate logistic regression analysis.

| | Unadjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
|--|------------------------|---------|----------------------|---------|
| Age ¹ | 1.01 (0.99–1.02) | 0.315 | Not included | |
| Gender: female ² | 0.96 (0.69–1.33) | 0.818 | Not included | |
| Pre-operative <i>S.aureus</i> colonization | 3.01 (2.23–4.20) | <0.001* | 3.08 (2.23–4.22) | <0.001* |
| BMI ¹ | 1.04 (1.02–1.07) | 0.001* | 1.02 (0.99–1.05) | 0.148 |
| Diabetes mellitus | 2.45 (1.78–3.34) | <0.001* | 1.87 (1.34–2.60) | <0.001* |
| Pre-operative antibiotic use | 0.67 (0.33–1.22) | 0.231 | Not included | |
| CABG | 3.10 (2.24–4.35) | <0.001* | 2.67 (1.91–3.78) | <0.001* |
| Vaccination | 0.67 (0.48–0.91) | 0.011* | 0.67 (0.48–0.91) | 0.012* |

* Significant at the 0.05 level. OR = odds ratio

1) OR per year of age or kg/M² increase

2) Male is reference category

<https://doi.org/10.1371/journal.pone.0193445.t002>




Fig 1. Calibration plot of final model, showing observed risks vs. predicted risks on the primary outcome.

<https://doi.org/10.1371/journal.pone.0193445.g001>

remained so after correction for other predictors (OR 0.67, 95% CI 0.48–0.91, $p = 0.012$). However, other predictor estimates did not change significantly after incorporating vaccination status, indicating a lack of confounding effect. Furthermore, because the development of this specific vaccine has been discontinued, vaccination was not included as a predictor in the final model.

Discussion

In this analysis, we built a risk prediction model to determine which preoperative characteristics put patients at higher risk of developing *S. aureus* SSI and/or bacteremia after cardiothoracic surgery. We identified *S. aureus* colonization, diabetes, increasing BMI, and CABG surgery as independent risk factors. The final prediction model using these readily available predictors performed satisfactorily.

As the frequency and impact of post-surgical infections remain substantial, the relevance of an accurate prediction model remains. Many previous studies have developed and validated




Fig 2. ROC curve of final model, with an AUC of 0.72 (95% CI 0.68–0.76).

<https://doi.org/10.1371/journal.pone.0193445.g002>

risk prediction tools for all-cause surgical site infection in cardiothoracic patients, some of which are frequently used in practice [22,23]. However, practical pathogen-specific models for postoperative *S. aureus* infections are scarce. Pathogen-specific prediction may be preferable, anticipating the arrival of targeted preventive measures in the near future [10,24–26]. Furthermore, patients suffering from *S. aureus* infections are at substantial risk for bad outcomes and incur higher health care costs [27–30]. This prediction model advances existing literature because it employs simple predictors routinely available in the preoperative patient. The risk difference between a patient not having any risk factor compared with one that has three is 10.1% (0.9% vs. 11.0%). However, in this derivation set, even though the predictors frequently occurred independently of each other, there were only 209 patients (2.7%) having all three factors, still leaving many patients at low or intermediate risk. A previous study by Kanafani et al. showed similar results [9]. Better discrimination between infected and non-infected patients is required to identify a larger patient group that would benefit from new interventions. Comprehensive prospective studies will be required, such as the prospective cohort study called




Fig 3. Boxplot showing distribution of predicted risks stratified for groups with/without primary outcome.

<https://doi.org/10.1371/journal.pone.0193445.g003>

ASPIRE-SSI (Advanced Understanding of Staphylococcus Aureus Infections in Europe—Surgical Site Infections), which is part of the COMBACTE-NET initiative[31,32]. This study will describe risk factors for *S. aureus* SSI of approximately 5000 patients across Europe undergoing different types of surgery and is currently ongoing.

A possible option for new model developers could be to use an established, validated prediction score like Euroscore and assess whether adding pathogen-specific variables like colonization status can make the model pathogen-specific[33]. This could have wider implications, considering that implementation would not require any major change in routine practice, should the new prediction model be successful. The recently published ‘*Global guidelines on the prevention of surgical site infection*’ specifically stress the need for such a simple, inexpensive screening process, considering that in low- and middle-income countries the logistical and financial burdens that come with a screening and decolonization intervention may be too burdensome to implement on all preoperative patients [34].

A major strength of the current study is the size of the study and the number of participating countries/centers. Furthermore, data collection and patient follow-up was stipulated by protocol and closely monitored, minimizing the amount of missing data during follow-up,

and ensuring a high proportion of patients screened for *S. aureus* colonization unlikely to occur outside the setting of a clinical trial. Last, but not least, the statistical analyses performed here, including the sensitivity analyses taking into account competing risks were sophisticated and comprehensive.

There are several limitations to this analysis. First of all, decolonization strategies for *S. aureus* were neither standardized nor documented. Decolonization methods were likely applied to colonized patients at a majority of the sites [35]. If indeed accurate, this practice would decrease the difference in incidence rate of the primary outcome between colonized and non-colonized patients, as decolonization reduces infection rates in carriers [36,37].

Furthermore, in this study only nares were screened for *S. aureus* colonization, thus, carriage on skin or at other sites may have been missed. In other words, there is potential misclassification bias, since some of the “non-colonized” patients may have been colonized elsewhere. This misclassification likely would be independent of *S. aureus* bacteremia and SSI, giving rise to a non-differential misclassification of the *S. aureus* carrier status. The non-differential misclassification may have biased our estimates towards the null and reduced the discriminative effect of the new prediction model.

Despite the limitations described above, the model performed moderately well. In its present form it may only be useful to indicate an especially high risk for patients having all three risk factors. For subtler prediction and external validation, further enhancement of the model is necessary.

Conclusion

From this analysis, we can conclude that pre-operative *S. aureus* colonization gives a 3x higher OR for *S. aureus* SSI / bacteremia in the unsubstantiated (but likely) presence of decolonization procedures. Without decolonization, the risk is likely to be higher. This model that included colonization status, diabetes, and CABG had overall average performance.

Supporting information

S1 File. Full list of approving ethics committees.
(DOC)

Acknowledgments

The authors would like to thank Dr. Flaminia Olearo (Geneva) for her contributions to the project.

Author Contributions

Conceptualization: Fleur P. Paling, Karina Olsen, Hasan S. Jafri, Frangiscos Sifakis, Marc J. M. Bonten, Stephan J. Harbarth, Jan A. J. W. Kluytmans.

Data curation: Fleur P. Paling, Karina Olsen, Kristin Ohneberg, Martin Wolkewitz.

Formal analysis: Fleur P. Paling, Karina Olsen, Kristin Ohneberg, Martin Wolkewitz.

Funding acquisition: Marc J. M. Bonten.

Investigation: Vance G. Fowler, Jr., Mark J. DiNubile.

Methodology: Fleur P. Paling, Karina Olsen, Kristin Ohneberg, Martin Wolkewitz, Frangiscos Sifakis, Marc J. M. Bonten, Stephan J. Harbarth, Jan A. J. W. Kluytmans.

Project administration: Vance G. Fowler, Jr., Mark J. DiNubile.

Resources: Vance G. Fowler, Jr., Mark J. DiNubile.

Software: Fleur P. Paling, Karina Olsen, Kristin Ohneberg, Martin Wolkewitz, Vance G. Fowler, Jr., Mark J. DiNubile.

Supervision: Mark J. DiNubile, Jan A. J. W. Kluytmans.

Validation: Fleur P. Paling, Karina Olsen, Kristin Ohneberg, Martin Wolkewitz, Stephan J. Harbarth, Jan A. J. W. Kluytmans.

Visualization: Fleur P. Paling, Karina Olsen, Kristin Ohneberg, Martin Wolkewitz.

Writing – original draft: Fleur P. Paling, Karina Olsen.

Writing – review & editing: Fleur P. Paling, Karina Olsen, Kristin Ohneberg, Martin Wolkewitz, Vance G. Fowler, Jr., Mark J. DiNubile, Hasan S. Jafri, Frangiscos Sifakis, Marc J. M. Bonten, Stephan J. Harbarth, Jan A. J. W. Kluytmans.

References

1. Douglas Scott II R, Promotion. NC for PD and C of ID (Centers for DC and PD of HQ. The Direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention No Title [Internet]. 2009. Available: https://www.cdc.gov/HAI/pdfs/hai/Scott_CostPaper.pdf
2. Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. *Infect Control Hosp Epidemiol.* 1999; 20: 725–30. <https://doi.org/10.1086/501572> PMID: 10580621
3. Gottlieb GS, Fowler VG, Kong LK, McClelland RS, Gopal AK, Marr KA, et al. Staphylococcus aureus bacteremia in the surgical patient: a prospective analysis of 73 postoperative patients who developed Staphylococcus aureus bacteremia at a tertiary care facility. *J Am Coll Surg.* 2000; 190: 50–7. Available: <http://www.ncbi.nlm.nih.gov/pubmed/10625232> PMID: 10625232
4. Young B, Ng TM, Teng C, Ang B, Tai HY, Lye DC. Nonconcordance with surgical site infection prevention guidelines and rates of surgical site infections for general surgical, neurological, and orthopedic procedures. *Antimicrob Agents Chemother.* 2011; 55: 4659–63. <https://doi.org/10.1128/AAC.00562-11> PMID: 21825293
5. Anderson DJ. Surgical site infections. *Infect Dis Clin North Am.* 2011; 25: 135–53. <https://doi.org/10.1016/j.idc.2010.11.004> PMID: 21315998
6. Anderson DJ, Kaye KS. Staphylococcal surgical site infections. *Infect Dis Clin North Am.* 2009; 23: 53–72. <https://doi.org/10.1016/j.idc.2008.10.004> PMID: 19135916
7. Wertheim HFL, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, et al. The role of nasal carriage in Staphylococcus aureus infections. *Lancet Infect Dis.* 2005; 5: 751–62. [https://doi.org/10.1016/S1473-3099\(05\)70295-4](https://doi.org/10.1016/S1473-3099(05)70295-4) PMID: 16310147
8. Gervaz P, Bandiera-Clerc C, Buchs NC, Eisenring M-C, Troillet N, Perneger T, et al. Scoring system to predict the risk of surgical-site infection after colorectal resection. *Br J Surg.* 2012; 99: 589–595. <https://doi.org/10.1002/bjs.8656> PMID: 22231649
9. Kanafani ZA, Arduino JM, Muhlbaier LH, Kaye KS, Allen KB, Carmeli Y, et al. Incidence of and preoperative risk factors for Staphylococcus aureus bacteremia and chest wound infection after cardiac surgery. *Infect Control Hosp Epidemiol.* 2009; 30: 242–8. <https://doi.org/10.1086/596015> PMID: 19199534
10. Kostyanov T, Bonten MJM, O'Brien S, Steel H, Ross S, François B, et al. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. *J Antimicrob Chemother.* Oxford University Press; 2016; 71: 290–5. <https://doi.org/10.1093/jac/dkv339> PMID: 26568581
11. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. *JAMA.* 2013; 309: 1368–78. <https://doi.org/10.1001/jama.2013.3010> PMID: 23549582
12. Allen KB, Fowler VG, Gammie JS, Hartzel JS, Onorato MT, DiNubile MJ, et al. Staphylococcus aureus Infections After Elective Cardiothoracic Surgery: Observations From an International Randomized Placebo-Controlled Trial of an Investigational S aureus Vaccine. *Open Forum Infect Dis.* 2014; 1: ofu071. <https://doi.org/10.1093/ofid/ofu071> PMID: 25734141
13. Centers for Disease Control. Surgical Site Infection (SSI) Event. 2014.

14. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. *Lancet* (London, England). 2007; 369: 482–90. [https://doi.org/10.1016/S0140-6736\(07\)60235-9](https://doi.org/10.1016/S0140-6736(07)60235-9)
15. Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. John Wiley & Sons;
16. Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ*. 2009; 338: b2393. <https://doi.org/10.1136/bmj.b2393> PMID: 19564179
17. Sauerbrei W. The Use of Resampling Methods to Simplify Regression Models in Medical Statistics. *J R Stat Soc Ser C (Applied Stat)*. Blackwell Publishers Ltd.; 1999; 48: 313–329. <https://doi.org/10.1111/1467-9876.00155>
18. Mittlböck M, Schemper M. Explained variation for logistic regression. *Stat Med*. 1996; 15: 1987–1997. [https://doi.org/10.1002/\(SICI\)1097-0258\(19961015\)15:19<1987::AID-SIM318>3.0.CO;2-9](https://doi.org/10.1002/(SICI)1097-0258(19961015)15:19<1987::AID-SIM318>3.0.CO;2-9) PMID: 8896134
19. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *J Am Stat Assoc*. 1999; 94: 496–509. <https://doi.org/10.1080/01621459.1999.10474144>
20. Allignol A, Schumacher M, Beyersmann J. A Note on Variance Estimation of the Aalen-Johansen Estimator of the Cumulative Incidence Function in Competing Risks, with a View towards Left-Truncated Data. *Biometrical J*. 2010; 52: 126–137. <https://doi.org/10.1002/bimj.200900039> PMID: 20140901
21. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing [Internet]. 2017. Available: <https://www.r-project.org>
22. Fowler VG, O'Brien SM, Muhlbaier LH, Corey GR, Ferguson TB, Peterson ED. Clinical predictors of major infections after cardiac surgery. *Circulation*. 2005; 112: I358–65. <https://doi.org/10.1161/CIRCULATIONAHA.104.525790> PMID: 16159846
23. Nashef SAM, Roques F, Hammill BG, Peterson ED, Michel P, Grover FL, et al. Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery. *Eur J Cardiothorac Surg*. 2002; 22: 101–5. Available: <http://www.ncbi.nlm.nih.gov/pubmed/12103381> PMID: 12103381
24. François B, Jafri HS, Bonten M. Alternatives to antibiotics. *Intensive Care Med*. 2016; 42: 2034–2036. <https://doi.org/10.1007/s00134-016-4339-y> PMID: 27033888
25. Giersing BK, Dastgheyb SS, Modjarrad K, Moorthy V. Status of vaccine research and development of vaccines for *Staphylococcus aureus*. *Vaccine*. 2016; 34: 2962–2966. <https://doi.org/10.1016/j.vaccine.2016.03.110> PMID: 27105559
26. Frenck RW, Buddy Creech C, Sheldon EA, Seiden DJ, Kankam MK, Baber J, et al. Safety, tolerability, and immunogenicity of a 4-antigen *Staphylococcus aureus* vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. *Vaccine*. 2017; 35: 375–384. <https://doi.org/10.1016/j.vaccine.2016.11.010> PMID: 27916408
27. Broex ECJ, van Asselt ADI, Bruggeman CA, van Tiel FH. Surgical site infections: how high are the costs? *J Hosp Infect*. 2009; 72: 193–201. <https://doi.org/10.1016/j.jhin.2009.03.020> PMID: 19482375
28. McGarry SA, Engemann JJ, Schmader K, Sexton DJ, Kaye KS. Surgical-site infection due to *Staphylococcus aureus* among elderly patients: mortality, duration of hospitalization, and cost. *Infect Control Hosp Epidemiol*. 2004; 25: 461–7. <https://doi.org/10.1086/502422> PMID: 15242192
29. Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Smulders M, et al. The burden of *Staphylococcus aureus* infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. *Arch Intern Med*. American Medical Association; 2005; 165: 1756–61. <https://doi.org/10.1001/archinte.165.15.1756> PMID: 16087824
30. Olsen MA, Krauss M, Agniel D, Schootman M, Gentry CN, Yan Y, et al. Mortality associated with bloodstream infection after coronary artery bypass surgery. *Clin Infect Dis*. 2008; 46: 1537–46. <https://doi.org/10.1086/587672> PMID: 18419488
31. Rex JH. ND4BB: addressing the antimicrobial resistance crisis. *Nat Rev Microbiol*. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.; 2014; 12: 231–232. <https://doi.org/10.1038/nrmicro3245>
32. Combatting Bacterial Resistance in Europe [Internet]. Available: www.combacte.com
33. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. *Eur J Cardiothorac Surg*. 1999; 15: 816–22–3. Available: <http://www.ncbi.nlm.nih.gov/pubmed/10431864> PMID: 10431864

34. Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de Vries F, et al. New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. *Lancet Infect Dis*. 2016; 16: e288–e303. [https://doi.org/10.1016/S1473-3099\(16\)30402-9](https://doi.org/10.1016/S1473-3099(16)30402-9) PMID: 27816414
35. Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Jacobson C, et al. Budget impact analysis of rapid screening for *Staphylococcus aureus* colonization among patients undergoing elective surgery in US hospitals. *Infect Control Hosp Epidemiol*. 2008; 29: 16–24. <https://doi.org/10.1086/524327> PMID: 18171182
36. Bode LGM, Kluytmans JAJW, Wertheim HFL, Bogaers D, Vandenbroucke-Grauls CMJE, Roosendaal R, et al. Preventing surgical-site infections in nasal carriers of *Staphylococcus aureus*. *N Engl J Med*. 2010; 362: 9–17. <https://doi.org/10.1056/NEJMoa0808939> PMID: 20054045
37. van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing *Staphylococcus aureus* infections in nasal carriers. *Cochrane database Syst Rev*. 2008; CD006216. <https://doi.org/10.1002/14651858.CD006216.pub2> PMID: 18843708